WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker released the following statement:
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today issued the following statement from Ashley Wittorf, Executive Director, AdvaMed Accel & Global Head, Investor Relations, on bipartisan legislation (HR 7917) introduced in the U.S. House of Representatives which will provide economic relief to small medtech companies impacted by the COVID-19 pandemic:
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest data from the association’s national testing registry.
WASHINGTON, D.C. – To ensure production of vital medical devices and diagnostic tests during this critical time and to help prevent future supply chain issues, the Advanced Medical Technology Association (AdvaMed) announced that it is expanding the VentConnect platform. The new MedDeviceNetwork platform (MedDeviceNetwork.org) will move beyond ventilators to include other complex medical technologies America’s patients and caregivers need in the continuing fight against COVID-19 and other future health care emergencies.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced that shipments of COVID-19 molecular diagnostic tests reached one million per day for the week ending July 24, based on the latest data from the association's National Testing Registry.
WASHINGTON, D.C. – In its latest action to help ensure the widespread availability of testing to detect and contain the coronavirus, the Advanced Medical Technology Association (AdvaMed) today announced the creation of a comprehensive, national COVID-19 diagnostic supply registry to help state and federal governments in their pandemic responses. The national registry is being launched in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.
WASHINGTON, D.C. – AdvaMed today sent the following letter to Health and Human Services (HHS) Secretary Azar requesting that he extend the declared federal public health emergency (PHE) beyond its current expiration date, so that the medical technology industry can continue to efficiently deliver the tools hospitals need to treat people with COVID-19. In light of recent reports that the PHE would likely be extended, AdvaMed president and CEO Scott Whitaker requested that the medical technology industry be given the opportunity to weigh in on any future decision to terminate the PHE.
WASHINGTON, D.C. - Today, 340 organizations signed a letter urging Congressional leaders to make telehealth flexibilities created during the COVID-19 pandemic permanent. Those signing this multi-stakeholder letter include national and regional organizations representing a full range of health care stakeholders and all 50 states, the District of Columbia, and Puerto Rico.
WASHINGTON, D.C. – The MedTech Conference, powered by AdvaMed, promises to continue its tradition of providing world-class programming for the medical technology community, announcing today that the conference will be an all-virtual experience for 2020, and that its plan to host the conference in Toronto will be pushed to 2022.
Our partners at the American Association of Blood Banks (AABB) sent us the following message to share with you: